CLRB · Cellectar Biosciences Inc
United States · RS rating 3 · As of 2026-10-14
| Price | 1.18 USD |
|---|---|
| 1-day change | -15.1% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 2 / 4 / 7 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 18 / 50 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +57.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +76.3% |
| Market cap (USD) | $11.8M |